A price on health

• Autores: Zara Aziz
• Localización: New scientist, ISSN 0262-4079, Nº. 3110, 2017, pág. 24
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Aziz determines whether costly drugs for rare diseases should be sidelined. This is the debate swirling around a proposal from the National Institute for Health and Care Excellence, a body that decides which treatments the NHS funds. It wants to change the thresholds for financing drugs to treat rare conditions. In broad terms, it recommends automatically funding them up to L100,000 per Quality-Adjusted Life Year, a way of judging the cost-effectiveness of a treatment. Although those above L100,000 may still be considered, critics say they would be much less likely to get through.